Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 7, 10.3322/caac.21551 Surveillance, Epidemiology and End Results Program, 2020 Choueiri, 2017, Systemic therapy for metastatic renal-cell carcinoma, N Engl J Med, 376, 354, 10.1056/NEJMra1601333 Kamli, 2019, Limitations to the therapeutic potential of tyrosine kinase inhibitors and alternative therapies for kidney cancer, Ochsner J, 19, 138, 10.31486/toj.18.0015 National Comprehensive Cancer Network, 2021 Viana, 2018, Therapeutic use of mTOR inhibitors in renal diseases: advances, drawbacks, and challenges, Oxid Med Cell Longev, 2018, 10.1155/2018/3693625 Zarrabi, 2017, New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy, J Hematol Oncol, 10, 38, 10.1186/s13045-016-0374-y US Food and Drug Administration, 2016 Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9 Gelber, 1995, Comparing treatments using quality-adjusted survival: the Q-TWiST method, Am Stat, 49, 161 Solem, 2018, Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology, Expert Rev Pharmacoecon Outcomes Res, 18, 245, 10.1080/14737167.2018.1434414 Qi, 2018, Calculating restricted mean survival time, Proceedings of PharmaSUG Reni, 2014, Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis, J Med Econ, 17, 338, 10.3111/13696998.2014.903122 Revicki, 2006, Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data, Qual Life Res, 15, 411, 10.1007/s11136-005-1579-7 Cella, 2016, Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial, Lancet Oncol, 17, 994, 10.1016/S1470-2045(16)30125-5 Lee, 2018, Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma, Ann Oncol, 29, viii14 Beaumont, 2016, Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma, Cancer, 122, 1108, 10.1002/cncr.29888 Chen, 2020, Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance), Cancer, 126, 5311, 10.1002/cncr.33169 Patil, 2012, Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α, Br J Cancer, 106, 1587, 10.1038/bjc.2012.149 Zbrozek, 2010, Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma, PharmacoEconomics, 28, 577, 10.2165/11535290-000000000-00000 Shah, 2019, A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab versus everolimus in advanced renal cell carcinoma (aRCC), Clin Genitourin Cancer, 17, 10.1016/j.clgc.2019.05.010 Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1814, 10.1056/NEJMoa1510016 Carmichael, 2013, Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors, Clin Genitourin Cancer, 11, 149, 10.1016/j.clgc.2012.09.006